Page last updated: 2024-08-16

ribavirin and stavudine

ribavirin has been researched along with stavudine in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (55.00)29.6817
2010's8 (40.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Alvarez, K; Balzarini, J; Barral, K; Canard, B; Neyts, J; Priet, S; Sire, J1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Campillo, NE; Guerra, A; Páez, JA1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Perronne, C1
Benech, H; Bonnet, E; Bouvier-Alias, M; Chêne, G; Goujard, C; Lassalle, R; Morlat, P; Payan, C; Pérusat, S; Pruvost, A; Salmon-Céron, D; Sogni, P; Tréluyer, JM; Zoulim, F1
Boxwell, D; Fleischer, R; Sherman, KE1
Ballesteros, AL; Clotet, B; Côté, H; Fuster, D; Garrabou, G; López, S; Martínez, E; Miró, O; Planas, R; Rey-Joly, C; Salas, A; Tor, J; Tural, C; Videla, S1
Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K1

Reviews

2 review(s) available for ribavirin and stavudine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
    Gastroenterologie clinique et biologique, 2002, Volume: 26 Spec No 2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine

2002

Trials

3 trial(s) available for ribavirin and stavudine

ArticleYear
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, May-15, Volume: 36, Issue:10

    Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferons; Male; Middle Aged; Ribavirin; RNA, Viral; Stavudine; Treatment Outcome; Viral Load

2003
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
    Antiviral therapy, 2004, Volume: 9, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors

2004
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10

    Topics: Adult; Area Under Curve; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Zidovudine

2005

Other Studies

15 other study(ies) available for ribavirin and stavudine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
    Journal of medicinal chemistry, 2006, Dec-28, Volume: 49, Issue:26

    Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Boranes; Boron Compounds; Chlorocebus aethiops; DNA Viruses; HIV-1; Humans; In Vitro Techniques; Nucleosides; Organophosphonates; Phosphates; RNA Viruses; Structure-Activity Relationship; Vero Cells; Virus Replication

2006
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:3

    Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Nucleoside analogues and mitochondrial toxicity.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Apr-15, Volume: 38, Issue:8

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Mitochondria; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine

2004